Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Cytokinetics Incorporated, 3 years.
Cytokinetics Incorporated
Director
Alkermes plc
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Cytokinetics Incorporated May 27, 202697.2%
-
Cytokinetics Incorporated May 10, 202394.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 15, 2026 | Cytokinetics Incorporated | Grant or award | +75 | $82.62 | $6,197 |
| May 27, 2026 | Cytokinetics Incorporated | Grant or award | +2,851 | — | — |
| Apr 15, 2026 | Cytokinetics Incorporated | Grant or award | +95 | $65.37 | $6,210 |
| Jan 15, 2026 | Cytokinetics Incorporated | Grant or award | +98 | $63.44 | $6,217 |
| Oct 15, 2025 | Cytokinetics Incorporated | Grant or award | +99 | $62.80 | $6,217 |
| Jul 15, 2025 | Cytokinetics Incorporated | Grant or award | +164 | $38.01 | $6,234 |
| May 14, 2025 | Cytokinetics Incorporated | Grant or award | +7,333 | — | — |
| Apr 15, 2025 | Cytokinetics Incorporated | Grant or award | +162 | $38.56 | $6,247 |
| Jan 2, 2025 | Cytokinetics Incorporated | Grant or award | +127 | $48.93 | $6,214 |
| Oct 1, 2024 | Cytokinetics Incorporated | Grant or award | +118 | $52.60 | $6,207 |
| Jul 1, 2024 | Cytokinetics Incorporated | Grant or award | +114 | — | — |
| May 15, 2024 | Cytokinetics Incorporated | Grant or award | +5,600 | — | — |
| Jan 2, 2024 | Cytokinetics Incorporated | Grant or award | +74 | $84.12 | $6,225 |
| Oct 2, 2023 | Cytokinetics Incorporated | Grant or award | +224 | $27.88 | $6,245 |
| Jul 7, 2023 | Alkermes plc | Option exercise | +5,957 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.